A Multi-center, Single-arm, Open-label Phase 2 Trial of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection with Hemophilia
Latest Information Update: 20 Mar 2025
At a glance
- Drugs Foscenvivint (Primary)
- Indications Liver cirrhosis
- Focus Therapeutic Use
- Acronyms OP-724-H201
Most Recent Events
- 17 Mar 2025 Planned End Date changed from 30 Jun 2025 to 31 Mar 2026.
- 17 Mar 2025 Planned primary completion date changed from 31 Mar 2025 to 31 Dec 2025.
- 30 Dec 2024 Status changed from recruiting to active, no longer recruiting.